move sidelin face hcv
report financi result includ hcv royalti ep
line consensu stock come pressur vs nbi flat
sinc report strong hcv revenu set
guidanc fuel investor fear hcv sale peak
also esrx releas nation prefer formulari list exclud mavyret
favor hcv drug updat may signal continu hcv price competit
toplin encourag data rsv studi addit
major catalyst potenti pressur hcv move
sidelin perform rate pt
report hcv royalti mavyret viekira sale
estim royalti vikera royalti sale
mavyret blend royalti sale exhibit
hcv guidanc indic q/q decreas sale vs
model
hcv sale forecast impact esrx nation prefer
formulari list releas state pbm prefer drug mavyret esrx
among largest pharmaci exhibit exclud mavyret
although negoti on-going see move sign
continu price pressur hcv impact sale
point hcv sale us
patient privat indic today updat limit impact consid
histor impact previou us price formulari exclus thu
revis near term hcv sale model exhibit result decreas cash
flow impact dcf valuat pt
separ encourag manag comment regard result
develop rsv seriou infect signific
unmet need young infant view result highli de-risk
consid similar dose regimen test potenti
registr clinic trial view mechan key differenti
next signific clinic catalyst like result
pbc nash studi continu enrol patient earli
next year readout absenc near-term catalyst
off-set continu hcv headwind updat model downgrad
perform outperform lower pt prior
compani use robust chemistry-
driven approach drug discoveri
capabl creat small molecul
diseas enanta research
current focus hepat viru
nash /pbc respiratori syncyti
analyst certif import disclosur see disclosur
infect
viral
assum hcv royalti fund on-going develop
pipelin asset potenti bd
assum hcv stabl
assum develop nash pbc
enta uniqu approach drug develop focus
thorough optim compound could provid competit
advantag nash pbc compani success
demonstr hcv mavyret expect continu
perform mavyret hcv deliv royalti fund
develop new pipelin asset nash pbc hbv
select hbv candid
nash pbc data
acceler enter market
estim pbc nash respect
greater expect sale mavyret
hvb rsv product enter progress
fail develop nash pbc
mavyret fail defend market share
price target base dcf valuat methodolog see exhibit
key downsid risk price target clinic develop risk regulatori risk current phase trial addit
risk come lower expect peak sale market hcv drug due higher anticip competit
failur gain support medic commun healthcar prescrib third-parti payor risk relat partnership
novarti legal challeng patent protect product
exhibit hcv royalti forecast calendar year basi assum tier
royalti tier model hcv sale mavyret sale ytd
hcv sale leav reach lower end guidanc signal
gradual slow
exhibit new script nrx total script mavyret us suggest may
mavyret like achiev peak penetr us hcv market
risk un-adjust revenu sale sale mavyret sale viekira sale royaltiesof sale mavyret royalti viekira blend royalti mavyret tier rate opco mavyret tier rate opco mavyret tier rate opco mavyret tier rate opco mavyret tier rate opco cumul mavyret tier cumul mavyret tier cumul mavyret tier cumul mavyret tier hcv
exhibit although commentari suggest stabl hcv market suspect
announc esrx nation prefer formulari list exclud mavyret favor
drug repres potenti headwind
exhibit us rank pharmaci revenu esrx one largest pharmaci
exclud mavyret negoti on-going
sourceinterpretationquoteabbv callmatur us expan ex-usglob hcv sale million first quarter global mavyret sale nearli million mavyret continu strong launch trajectori intern market mavyret achiev market share current access three-quart cover live major access pariti mavyret establish strong posit major countri well japan germani spain itali abbv beat driven japanif look first quarter exampl signific warehous volum built japan saw patient ultim daa failur come treatment paradigm mavyret thereabbv calland creat phenomenon get fairli signific increas patient volum follow drop abbv calllarg patient pool remaininga look look global treatment volum long-rang plan calcul roughli long-rang plan see global world-wide patient time trend even end period time still patient base calcul abbv callmarket leader gildw gain leadership posit mani signific market around world realli boil two-compani market us gilead expect chang forese futur abbv callpric stabl say price part stabl sinc mavyret launch seen situat germani exampl saw merck essenti come take aggress price posit chang price fairli signific way germani say recent exampl price assum price stay rel stabl period time think assum market share posit stay rel stabl would say maintain kind market share posit long rang plan callsustain revenu result abbvi increas global hcv sale guidanc calendar year approxim billion addit abbvi provid calendar year second quarter hcv guidanc million correl enanta fiscal third quarter perform
exhibit updat lead revis mavyret sale forecast
exhibit hypothet sotp valuat methodolog use pt includ
rsv hbv
sale ww new mavyret estimateprevi mavyret estimatedrug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successp-adj npv mm sotp p-adj valu shareroyalti equiti share outstand use valuat oppenheim co enanta inc
exhibit dcf valuat support
discount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu oppenheim co equiti valu per sharetermin valu growth rate perform
nash
probabl success
pbc
probabl success
collabor revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex
stock price compani mention report aug
